The Journal of Clinical Psychiatry
September 3, 2025
Kristina T. Kumpf, Samuel T. Wilkinson, Bo Hu et al.
Electroconvulsive therapy (ECT) has potent antidepressant effects yet can lead to neurocognitive side effects. Ketamine is a rapid-acting antidepressant, which may be an alternative to ECT. Few have directly compared the cognitive effects of ECT and ketamine treatment. We compared cognitive effects of intravenous ketamine and ECT in patients with treatment-resistant depression (TRD), collected...
Psychiatry Research
May 1, 2025
Gerard Sanacora, Brian S. Barnett, Bo Hu et al.
2 citations
Previous studies have shown patient preference can have large effects on treatment adherence and patient satisfaction. However, the direct effects of matching treatment with patient preference on efficacy and safety outcomes remain unclear. We aimed to evaluate the effects of patient preference and preference-matching on efficacy, adverse events, and adherence to electroconvulsive therapy (ECT)...
Contemporary Clinical Trials
February 1, 2025
Noreen A Reilly-Harrington, Tatiana Falcone, David A Jobes et al.
Suicide is a leading cause of death in young persons. While ketamine has demonstrated rapid anti-suicidal effects, its safety and efficacy in youth has not been fully investigated. The Collaborative Assessment and Management of Suicidality (CAMS), a suicide-focused treatment shown to decrease suicidal ideation and symptom distress, has never been studied in combination with ketamine. This study...
JAMA Network Open
June 3, 2024
Manish Kumar Jha, Samuel T. Wilkinson, Kamini Krishnan et al.
29 citations
The ELEKT-D: Electroconvulsive Therapy (ECT) vs Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D) trial demonstrated noninferiority of intravenous ketamine vs ECT for nonpsychotic TRD. Clinical features that can guide selection of ketamine vs ECT may inform shared decision-making for patients with TRD. To evaluate whether selected clinical features were associated with...
JAMA Psychiatry
December 1, 2023
Sanjay J. Mathew, Manish K. Jha, Amit Anand
8 citations
This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).
Psychiatry Research Case Reports
August 20, 2023
Brian S. Barnett, Amit Anand
Though usually mild, neuropsychiatric side effects of intravenous ketamine for depression occasionally result in treatment discontinuation. Two small clinical trials of healthy subjects have indicated that lamotrigine pre-treatment may attenuate these side effects, though two other trials, one in patients with unipolar depression and one in healthy male volunteers, did not support these...
Psychiatric Annals
February 1, 2020
Hatice Guncu Kurt, Murat Altinay, Amit Anand
Patients who have not responded to two antidepressant trials in their current depressive episode are usually considered to have treatment-resistant depression (TRD). A detailed search on PubMed was conducted for reported response and remission rates for non-ketamine and ketamine treatments for TRD. From a variety of pharmacological and brain stimulation open-label studies, the treatments were...
Journal of Affective Disorders
2020
Roman M Dale, Kelly A. Bryant, Nora Finnegan et al.
17 citations
There are many putative mechanisms by which ketamine has its effect and many unanswered questions about risks and benefits of long-term ketamine therapy. A research imperative is the identification of predictors of response to intravenous ketamine, especially a sustained response to maintenance ketamine. Temperament is an inherited aspect of personality and is a predictive factor for outcome in...
Archives of General Psychiatry
March 1, 2000
Amit Anand, Dennis S. Charney, Dan A. Oren et al.
425 citations
BACKGROUND: The cognitive, behavioral, and mood effects of N-methyl-D-aspartate (NMDA) receptor antagonists, such as phencyclidine and ketamine, have been used to study the effects of NMDA receptor dysfunction. Pharmacological modulation of the effects of NMDA receptor antagonists, such as ketamine, may lead to development of novel therapeutic agents for psychiatric illnesses such as...